Updates in the Treatment of Lung Cancer




Release Date: December 22, 2014 | Expiration Date: December 22, 2015
Media: Print with online posttest, evaluation, and request for credit

Overview

The International Lung Cancer Congress® was held July 31 to August 2 in Huntington Beach, CA. The meeting serves as an update on advances in the lung cancer field with a focus on the clinical implications of the rapid changes in treatment options--novel agents, strategies, and improved regimens. The State of the Art segment of the agenda focused on the key treatment areas--novel agents, molecular testing, and maintenance therapy. This article reviews anti-angiogenetic therapy, next-generation EGFR TKIs, ALK inhibitors, acquired resistance, and maintenance therapy, providing physicians who could not attend the live meeting the opportunity to engage in the education.

Instructions For This Activity & Receiving Credit

  • You will need to login to participate in the activity.
  • Each presentation may contain an interactive question(s). You may move forward through the presentation; however, you may not go back to change answers or review videos/content until you finish the presentation.
  • At the end of the activity, "educational content/video" will be available for your reference.
  • In order to receive a CME certificate, participants must complete the activity.
  • Complete the posttest and pass with a score of 70% or higher, complete the evaluation and then click on request for credit.  Participants may immediately download a CME certificate upon completion of these steps.


Target Audience

This activity is directed toward medical oncologists and hematologists who treat patients with solid tumors and hematologic malignancies. Fellows, nurses, physician assistants, nurse practitioners, and other healthcare providers may also participate.


Learning Objectives

After participating in this CME activity, learners should be better prepared to:
  • Discuss strategies to improve care for patients with lung cancer
  • Review current standards and emerging data regarding systemic therapies for the treatment of advanced non-small cell lung cancer


Medical Writer

Cheryl Zigrand
Disclosure:
No relevant financial relationships with commercial interests to disclose.


The American Journal of Hematology/Oncology Editorial Board Member

Debu Tripathy, MD
Professor of Medicine and Chair
Department of Breast Medical Oncology
The University of Texas MD Anderson Cancer Center
Houston, TX

Disclosure: Genentech/ Roche, Pfizer, Puma, Inc. (clinical trial support contracted to University of Southern California); Consultant: Eisai, Novartis


Staff/Planner Disclosures and Conflict of Interest Resolution

The staff of PER® (Debbie Augustus, Ann C. Lichti, CCMEP and Megan O'Connell) as well as the Editorial Staff of The American Journal of Hematology/Oncology (Devera Pine) have no relevant financial relationships with commercial interests to disclose.

In accordance with ACCME's Standards for Commercial SupportSM, PER® resolved all conflicts of interest (COI) prior to the release of this CME activity using a multistep process.


Accreditation/Credit Designation

Physicians’ Education Resource®, LLC, is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Physicians’ Education Resource®, LLC, designates this enduring material for a maximum of 1.0 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.


Acknowledgment of Commercial Support

This activity is funded entirely by Physicians’ Education Resource®.


Off-Label Disclosure and Disclaimer

This CME activity may or may not discuss investigational, unapproved, or off-label use of drugs. Participants are advised to consult prescribing information for any products discussed. The information provided in this CME activity is for continuing medical education purposes only, and is not meant to substitute for the independent medical judgment of a physician relative to diagnostic and treatment options for a specific patient's medical condition.


Disclaimer

The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER®.


Hardware And Software Requirements

Supported Browsers
Internet Explorer v.7 or greater (for Windows) | Mozilla Firefox v.2 or greater (for Windows, Mac, Linux)

Minimum System Requirements (Windows)
  • A Pentium-based PC or compatible computer
  • At least 64MB of RAM
  • Windows 95/98/NT/ME/2000/XP/Vista system software
  • Screen resolution of 1024 x 786 or larger recommended
  • PDF Reader: Adobe Reader 5.0 or higher, Foxit Reader 2.0 or likewise
Minimum System Requirements (Mac OS)
  • A PowerPC processor-based Macintosh computer
  • At least 64MB of RAM
  • Mac OS 7.5 or later
  • Screen resolution of 1024 x 786 or larger recommended
  • PDF Reader: Adobe Reader 5.0 or higher, Foxit Reader 2.0 or likewise
     

Calendar of Events
SUNMONTUESWEDTHURSFRISAT
     12
3456789
10111213141516
17181920212223
24252627282930
31
Filter By

VSEO N/A